Business, energy, technology, markets and global industry news from Business News Today

Eli Lilly and Company

PharmaDeviceNews Eli Lilly and Company
Eli Lilly’s investigational retatrutide delivered significant weight loss and A1C improvements in the Phase 3 TRIUMPH-2 and TRIUMPH-3 obesity trials. Representative image.
Pharma & Biotech

Retatrutide TRIUMPH-3 trial advances Eli Lilly’s 2027 FDA filing plan

Eli Lilly’s retatrutide delivered up to 22.6% weight loss in two Phase 3 trials as a 2027 FDA filing moves closer.

Read More
Novellia’s GLP-1 and Metabolic Health Registry aims to track weight outcomes, treatment persistence and coverage disruptions across complex patient journeys, addressing evidence gaps left by traditional healthcare datasets. Representative image.
Pharma & Biotech

Novellia’s GLP-1 registry found a surprising weight-loss pattern, but what does it really prove?

See how Novellia’s GLP-1 registry could sharpen real-world evidence while facing tests on validation, bias, privacy and payer use.

Read More
Representative image: A monitored sleep study and oral medication illustrate Incannex Healthcare’s DReAMzz Phase 2 screening program as the company refines IHL-42X dosing before a planned Phase 3 obstructive sleep apnea trial.
Pharma & Biotech

Incannex Healthcare begins DReAMzz screening to refine IHL-42X dosing before Phase 3 sleep apnea trial

Incannex Healthcare begins DReAMzz screening to select an IHL-42X dose before Phase 3. Read what the sleep apnea study must prove.

Read More
Eli Lilly’s up to US$3.8 billion AtaiBeckley deal raises interest in BPL-003 and the expanding psychedelic medicine pipeline. Representative image.
Pharma & Biotech

Eli Lilly’s psychedelic deal carries a US$3.8bn headline, but the fine print tells the real story

Eli Lilly’s AtaiBeckley deal brings psychedelic medicine into big pharma’s M&A race, but Phase 3 data and rescheduling still decide its value.

Read More
AdvanCell’s US$315 million financing supports ADVC001 prostate cancer trials and expanded Lead-212 radiopharmaceutical manufacturing. Representative image.
Pharma & Biotech

Why investors just put $315m behind AdvanCell’s prostate cancer alpha therapy

AdvanCell’s US$315 million Series D backs ADVC001 trials and Lead-212 manufacturing, but Phase 2 evidence remains the decisive test.

Read More
Representative image: Alchemab Therapeutics’ £25 million funding supports AI-enabled antibody discovery, Resiliome expansion and new clinical programs.
Pharma & Biotech

Why British Business Bank just made its biggest life sciences bet on Alchemab Therapeutics

Alchemab Therapeutics secures £25 million to double its antibody data and advance two wholly owned programs toward clinical development.

Read More
Pharma & Biotech

Evidation GLP-1 study reveals major growth runway but exposes widening access gaps

Discover how Evidation’s 165,000-person study reveals GLP-1 growth potential, access gaps and persistence risks shaping obesity care. Read more.

Read More
Representative image: Advanced antibody and immune-cell research highlights TRexBio’s TRB-071 CD30 agonist programme and Eli Lilly and Company-partnered TRB-051 as both candidates progress in autoimmune disease development.
Pharma & Biotech

Lilly advances TRB-051 in lupus as TRexBio unveils the mechanism behind TRB-071

Explore how TRexBio’s TRB-071 CD30 agonist and Lilly-partnered TRB-051 could reshape tissue Treg drug development. Read the analysis.

Read More
Representative image of scientists reviewing liver biomarker and RNA-editing data as ProQR Therapeutics advances AX-0810 and AX-0811 in the race to develop a treatment for biliary atresia.
Pharma & Biotech

ProQR shows RNA editing works in humans, but can AX-0810 delay liver transplantation?

ProQR Therapeutics has produced the first human target-engagement evidence for its Axiomer RNA-editing platform. The results support its mechanism, but patient benefit, long-term safety and the choice between AX-0810 and AX-0811 remain unresolved.

Read More
Representative image: AI-driven protein design in a modern biotech lab, reflecting Chai Discovery’s Lilly TuneLab collaboration to expand miniprotein discovery tools for select biotechs.
Pharma & Biotech

Chai Discovery tests a new commercial route for AI-designed biologics through Lilly TuneLab

Explore how Chai Discovery and Lilly TuneLab are widening biotech access to AI miniprotein design and what must happen next.

Read More